Quantcast
Last updated on April 16, 2014 at 13:29 EDT

Latest tumor treating fields Stories

2013-12-20 08:25:46

SYDNEY, Dec. 20, 2013 /PRNewswire/ -- Novogen Limited, an oncology drug development company, announced today the signing of a Sponsored Research Agreement with Cornell University. The Weill Cornell Medical College (WCMC) in New York will become the cornerstone of a collaboration across Europe, US, Asia and Australia involving universities and biotechnology companies seeking a treatment capable of delivering long-term remission for the main form of primary brain cancer, glioblastoma...

2013-11-18 08:30:09

Neuro-Oncology experts from around the world will gather in San Francisco where data supporting the role of Tumor Treating Fields (TTFields) in treating recurrent glioblastoma brain tumors will be presented ST. HELIER, Jersey, Nov. 18, 2013 /PRNewswire/ -- Novocure announced today that 15 preclinical and clinical abstracts describing the latest aspects of NovoTTF(TM) Therapy will be presented at the 4(th) Quadrennial Meeting of the World Federation of Neuro-Oncology (WFNO), which is...

2013-11-05 08:36:35

The NovoTAL System Enables Certified Physicians to Plan and Individualize NovoTTF(TM) Therapy for Recurrent Glioblastoma Patients NEW YORK, Nov. 5, 2013 /PRNewswire/ -- Novocure announced today that the United States Food and Drug Administration (FDA) has approved the NovoTAL (Transducer Array Layout) System through a Premarket Approval (PMA) supplement. The NovoTAL System allows certified physicians to use the individual MRI data of recurrent glioblastoma multiforme (GBM) patients...

2013-09-04 08:30:38

-- Phase I/II study showed the addition of NovoTTF Therapy to pemetrexed is safe and potentially more effective than pemetrexed alone for second line NSCLC ST. HELIER, Jersey, Sept. 4, 2013 /PRNewswire/ -- Results of the first clinical trial to study treatment with tumor treating field therapy (NovoTTF Therapy) in combination with chemotherapy for patients with non-small cell lung cancer (NSCLC) were published in the journal Lung Cancer. The study demonstrated that combining NovoTTF...

2013-05-31 08:25:09

PORTSMOUTH, N.H., May 31, 2013 /PRNewswire/ -- Novocure, a commercial stage private oncology company, announced today that data from pre-clinical and clinical studies evaluating NovoTTF(TM) Therapy will be presented and published online as part of the 49th Annual Meeting of the American Society for Clinical Oncology (ASCO) in Chicago, IL, May 31-June 4, 2013. The clinical data includes a detailed analysis of time to tumor progression for patients with recurrent glioblastoma treated with...

2013-05-02 12:28:31

Novocure Inc. Launches Social Media Campaign to Help Elevate Awareness and Understanding of Deadly Disease PORTSMOUTH, N.H., May 2, 2013 /PRNewswire/ -- Today, Novocure Inc. launched the Tune-In to GBM campaign, a public call to action to "Tune-In" to glioblastoma (GBM) during National Brain Cancer Awareness Month. As part of the campaign, Novocure will provide donations to three non-profit organizations dedicated to supporting brain cancer patients and their families: the Musella...

2012-11-14 12:26:45

PORTSMOUTH, N.H., Nov. 14, 2012 /PRNewswire/ -- Novocure(TM), a commercial stage private oncology company, announced today that preclinical and clinical data from studies evaluating NovoTTF(TM) Therapy will be presented at the 17th Annual Scientific Meeting and Education Day of the Society for Neuro-Oncology (SNO) in Washington, D.C. The data presented sheds light on the subcellular mechanisms underlying the anti-cancer effect of NovoTTF Therapy and helps define which recurrent GBM...

2012-11-08 08:35:29

VANCOUVER, British Columbia, Nov. 8, 2012 /PRNewswire/ -- Del Mar Pharmaceuticals (BC) Ltd. (DelMar) today announced that Mr. Jeffrey Bacha, the Company's President & CEO, delivered the keynote address entitled VAL-083 a Novel Chemotherapeutic Agent Developed in China for CML and Lung Cancer Shows Potential to Surpass Standard of Care in Glioblastoma Multiforme at the 2012 International Drug Discovery Science and Technology Conference in Nanjing, China. In his address, Mr. Bacha...

2012-11-06 04:20:49

HEIDELBERG, Germany, Nov. 6, 2012 /PRNewswire/ -- Apogenix, a clinical stage biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases, today announced that its lead product, Apocept(TM) (APG101), has been selected by Elsevier Business Intelligence and Windhover Conferences as one of oncology's "Top 10 Projects To Watch." This announcement is in conjunction with the "Therapeutic Area Partnerships" conference event taking place in...